Back

Impact of Dapaglizofin on right ventricular function and pulmonary pressure: a secondary analysis of the RIVED registry

9 May 2026 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: Medical treatment in acute heart failure Pharmacotherapy Delegates Premium Access Heart Failure 2026 Heart Failure Association (HFA)

About the speaker

Photo
Associate Professor Alberto Palazzuoli

University of Siena, Siena (Italy)

5 More presentations in this session

Presentation thumbnail
Association of poor adherence to guideline-directed medical treatment with adverse events including fatal arrhythmia in heart failure with reduced ejection fraction: A nationwide cohort analysis
Doctor M. Kim (Goyang, KR)
Abstract
Presentation thumbnail
Dapagliflozin in patients hospitalised with newly diagnosed heart failure: an analysis of the randomized DAPA ACT HF-TIMI 68 trial
Doctor P. Haller (Vienna, AT)
Abstract
Presentation thumbnail
Impact of LVEF and de novo heart failure on outcomes of SGLT2 inhibitor therapy initiated during acute heart failure
Doctor A. Castro Pinto (Guimaraes, PT)
Abstract
Presentation thumbnail
The O-GlcNAcase inhibitor ASN90 opposes acute cardiac decompensation in rats with chronic heart failure.
Doctor G. Vincent (Rouen, FR)
Abstract
Presentation thumbnail
Potentially inappropriate medications in older adults with heart failure: prevalence and predictors using the 2023 Beers Criteria
Doctor M. Sheikh-Taha (Blat, LB)
Abstract

Access the full session

Session thumbnail
Medical treatment in acute heart failure

The Event

Event poster

Heart Failure 2026

9 May - 12 May 2026
You may be interested in
thumbnail
Congress Session
Acute heart failure therapies: from clinical trials to clinical practice
thumbnail
Congress Session
Devices in acute heart failure
thumbnail
Congress Session
Guideline-directed medical therapy implementation in special clinical scenarios

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources